Fusion Pharmaceuticals Inc. (FUSN) Tops Q2 EPS by 1c

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) reported Q2 EPS of ($0.38), $0.01 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $34 thousand versus the consensus estimate of $84.38 thousand.

For earnings history and earnings-related data on Fusion Pharmaceuticals Inc. (FUSN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c